1. Brennan B, Stiller C, Bourdeaut F. Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncol. 2013;14(8):e329-e336. doi:10.1016/S1470-2045(13)70088-3
2. Brennan B, De Salvo GL, Orbach D, et al. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study - EpSSG NRSTS 2005. Eur J Cancer. 2016;60:69-82. doi:10.1016/j.ejca.2016.02.027
3. Brennan BMD, Foot ABM, Stiller C, et al. Where to next with extracranial rhabdoid tumours in children. Eur J Cancer. 2004;40(4):624-626. doi:10.1016/j.ejca.2003.11.014
4. Xi W, Sansam CG, Thom CS, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res. 2009;69(20):8094-8101. doi:10.1158/0008-5472.CAN-09-0733
5. Sood R, Kamikubo Y, and Liu P.P Role of RUNX1 in hematological malignancies. Blood. 2017 Apr 13;129(15):2070-2082. doi: 10.1182/blood-2016-10-687830. Epub 2017 Feb 8.
6. Kamikubo Y, Zhao L, Wunderlich M, et al. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell. 2010 May 18;17(5):455-68. doi: 10.1016/j.ccr.2010.03.022. Page 13 of 21 Pediatric Blood & Cancer
7. Kamikubo Y. Genetic compensation of RUNX family transcription factors in leukemia. Cancer Sci. 2018 Jun 8. doi: 10.1111/cas.13664.
8. Janes KA. RUNX1 and its understudied role in breast cancer. Cell Cycle. 2011;10(20):3461-3465. doi:10.4161/cc.10.20.18029
9. Hong D, Messier TL, Tye CE, et al. Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition. Oncotarget. 2017;8(11):17610-17627. doi:10.18632/oncotarget.15381
10. Morita K, Suzuki K, Maeda S, et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. J Clin Invest. 2017;127(7):2815-2828. doi:10.1172/JCI91788
11. Bando T, Sugiyama H. Synthesis and Biological Properties of Sequence-Specific DNA-Alkylating Pyrrole−Imidazole Polyamides. Acc Chem Res. 2006;39(12):935- 944. doi:10.1021/ar030287f
12. Minoshima M, Bando T, Shinohara K, Sugiyama H. Molecular design of sequence specific DNA alkylating agents. Nucleic Acids Symp Ser (Oxf). 2009;(53):69-70. doi:10.1093/nass/nrp035
13. Morita K, Maeda S, Suzuki K, et al. Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 2017;1(18):1440-1451. doi:10.1182/bloodadvances.2017007591
14. Morita K, Noura M, Tokushige C, et al. Autonomous feedback loop of RUNX1- p53-CBFB in acute myeloid leukemia cells. Sci Rep. 2017;7(1):16604. doi:10.1038/s41598-017-16799-z Pediatric Blood & Cancer Page 14 of 21
15. Mitsuda Y, Morita K, Maeda S, et al. RUNX1 positively regulates ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci Rep. 2018 Apr 23;8(1):6423. doi: 10.1038/s41598-018-24969-w.
16. Katsumi Y, Iehara T, Miyachi M, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochem Biophys Res Commun. 2011;413(1):62-68. doi:10.1016/j.bbrc.2011.08.047
17. Misawa A, Hosoi H, Imoto I, Iehara T, Sugimoto T, Inazawa J. Translocation (1;22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor. J Hum Genet. 2004;49(10):586-589. doi:10.1007/s10038-004-0191-y
18. Kuroda H, Moritake H, Sawada K, et al. Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. Cancer Genet Cytogenet. 2005;158(2):172-179. doi:10.1016/j.cancergencyto.2004.08.032
19. Morita K, Tokushige C, Maeda S, et al. RUNX transcription factors potentially control E-selectin expressions in the vascular niche of mice bone marrow. Blood Adv. 2018 Mar 13;2(5):509-515. doi:10.1182/bloodadvances.2017009324.
20. Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem. 2002;277(25):22330-22337.doi:10.1074/jbc.M111987200